Old malaria drug may tame lupus skin flares
NCT ID NCT07694336
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether quinacrine, a medication originally used for malaria, can safely reduce skin rashes and sores in people with cutaneous lupus erythematosus (CLE). Participants receive either quinacrine or a placebo for 12 weeks, then all receive quinacrine for another 12 weeks. The goal is to see if this drug, already used by some doctors, should become a standard treatment for CLE.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- quinacrine hydrochloride
- What this could lead to
- If it works, quinacrine could become a standard, FDA-approved treatment for cutaneous lupus, offering a new option for managing skin symptoms.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Quinacrine may not prove more effective than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.